Dermatitis atopic
Not recruitingStudy on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis
- Disease:Dermatitis atopic
- Substances:Rocatinlimab
Germany- Participants:18–64 years · 65+ years
- Substances:Rocatinlimab
- Sponsor:Amgen Inc.
Rare diseases
Investigational molecules
Locations
Back to Germany434 clinical trials in Kiel, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials focusing on breast cancer treatments, including studies of ribociclib with endocrine therapy for HR-positive, HER2-negative cases. Additional research encompasses various blood cancers, including lymphomas and leukemia.
Cutting-edge research evaluating novel therapeutic combinations and treatment approaches for better patient outcomes.
Comprehensive research into chronic skin conditions, including trials for plaque psoriasis and atopic dermatitis. Studies evaluate new therapeutic agents for moderate to severe cases.
Focus on developing effective treatments for persistent skin conditions that significantly impact quality of life.
Advanced studies in inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Trials investigate innovative therapies for moderate to severe cases.
Investigation of new therapeutic options for patients with inadequate response to conventional treatments.
Tell us about your condition – we search every trial in Europe and connect you with the right site.